Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 5
1982 6
1983 7
1984 5
1985 4
1986 3
1987 6
1988 10
1989 10
1990 17
1991 24
1992 23
1993 32
1994 36
1995 36
1996 41
1997 41
1998 69
1999 71
2000 75
2001 68
2002 76
2003 67
2004 70
2005 75
2006 72
2007 59
2008 67
2009 57
2010 63
2011 57
2012 60
2013 43
2014 74
2015 66
2016 58
2017 53
2018 60
2019 41
2020 58
2021 56
2022 41
2023 39
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

1,755 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
Papi A, Chipps BE, Beasley R, Panettieri RA Jr, Israel E, Cooper M, Dunsire L, Jeynes-Ellis A, Johnsson E, Rees R, Cappelletti C, Albers FC. Papi A, et al. N Engl J Med. 2022 Jun 2;386(22):2071-2083. doi: 10.1056/NEJMoa2203163. Epub 2022 May 15. N Engl J Med. 2022. PMID: 35569035 Clinical Trial.
BACKGROUND: As asthma symptoms worsen, patients typically rely on short-acting beta(2)-agonist (SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves patients at risk for severe asthma exacerbations. The use of a fixed-dose combination of albuterol a …
BACKGROUND: As asthma symptoms worsen, patients typically rely on short-acting beta(2)-agonist (SABA) rescue therapy, but SABAs do not addre …
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
The therapeutic potential of a novel, targeted-release formulation of oral budesonide (Nefecon) for the treatment of IgA nephropathy (IgAN) was first demonstrated by the phase 2b NEFIGAN trial. ...
The therapeutic potential of a novel, targeted-release formulation of oral budesonide (Nefecon) for the treatment of IgA nephropathy …
Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, Corin A, Sparks J, Hall D, Sabbagh D, Mane S, Vohlidkova A, Martindale J, Williams M, Shirtcliffe P, Holliday M, Weatherall M, Beasley R; PRACTICAL study team. Hardy J, et al. Lancet. 2019 Sep 14;394(10202):919-928. doi: 10.1016/S0140-6736(19)31948-8. Epub 2019 Aug 23. Lancet. 2019. PMID: 31451207 Clinical Trial.
Nasopharyngitis was the most common adverse event in both groups, occurring in 154 (35%) of 440 patients receiving as-needed budesonide-formoterol and 144 (32%) of 448 receiving maintenance budesonide plus terbutaline as needed. INTERPRETATION: In adults with mild t …
Nasopharyngitis was the most common adverse event in both groups, occurring in 154 (35%) of 440 patients receiving as-needed budesonide …
Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study.
Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Rabe KF, et al. Lancet. 2006 Aug 26;368(9537):744-53. doi: 10.1016/S0140-6736(06)69284-2. Lancet. 2006. PMID: 16935685 Clinical Trial.
After run-in, patients were randomly assigned budesonide-formoterol maintenance therapy plus one of three alternative as-needed medications-terbutaline (0.4 mg), formoterol (4.5 microg), or budesonide-formoterol (160 microg and 4.5 microg). ...The rate of severe exa …
After run-in, patients were randomly assigned budesonide-formoterol maintenance therapy plus one of three alternative as-needed medic …
Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis.
Beasley R, Harrison T, Peterson S, Gustafson P, Hamblin A, Bengtsson T, Fagerås M. Beasley R, et al. JAMA Netw Open. 2022 Mar 1;5(3):e220615. doi: 10.1001/jamanetworkopen.2022.0615. JAMA Netw Open. 2022. PMID: 35230437 Free PMC article.
DATA SOURCES: For this systematic review and meta-analysis, the literature, internal study databases at AstraZeneca and the Medical Research Institute of New Zealand, and references from a previous systematic review and meta-analysis on SMART were searched to identify randomized …
DATA SOURCES: For this systematic review and meta-analysis, the literature, internal study databases at AstraZeneca and the Medical Research …
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.
Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fagerås M. Bafadhel M, et al. Lancet Respir Med. 2018 Feb;6(2):117-126. doi: 10.1016/S2213-2600(18)30006-7. Epub 2018 Jan 10. Lancet Respir Med. 2018. PMID: 29331313 Clinical Trial.
METHODS: We analysed data from three AstraZeneca randomised controlled trials of budesonide-formoterol in patients with COPD with a history of exacerbations and available blood eosinophil counts. ...Only eosinophil count and smoking history were independent predictors of r …
METHODS: We analysed data from three AstraZeneca randomised controlled trials of budesonide-formoterol in patients with COPD with a h …
Budesonide for induction of remission in Crohn's disease.
Rezaie A, Kuenzig ME, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH, Kaplan GG, Seow CH. Rezaie A, et al. Cochrane Database Syst Rev. 2015 Jun 3;2015(6):CD000296. doi: 10.1002/14651858.CD000296.pub4. Cochrane Database Syst Rev. 2015. PMID: 26039678 Free PMC article. Review.
MAIN RESULTS: Fourteen studies (1805 patients) were included: Nine (779 patients) compared budesonide to conventional corticosteroids, three (535 patients) were placebo-controlled, and two (491 patients) compared budesonide to mesalamine. ...Studies comparing bud …
MAIN RESULTS: Fourteen studies (1805 patients) were included: Nine (779 patients) compared budesonide to conventional corticosteroids …
Effectiveness of Non-Budesonide Therapies in Management of Microscopic Colitis: A Systematic Review and Meta-analysis.
Rehde A, Hendel SK, Juhl CB, Gubatan J, Nielsen OH. Rehde A, et al. Drugs. 2023 Jul;83(11):1027-1038. doi: 10.1007/s40265-023-01914-4. Epub 2023 Jun 26. Drugs. 2023. PMID: 37358712
BACKGROUND: Budesonide is accepted as first-choice therapy for microscopic colitis (MC); however, symptoms often recur and some patients may be dependent, intolerant, or even fail budesonide. ...In addition, the overall evidence on the effect of these treatment opti …
BACKGROUND: Budesonide is accepted as first-choice therapy for microscopic colitis (MC); however, symptoms often recur and some patie …
Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial.
Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, de Souza Campos VH, Ferreira TS, Quirino Dos Santos CV, Ribeiro Nogueira AM, Figueiredo Guimaraes Almeida AP, Cançado Monteiro Savassi L, de Figueiredo Neto AD, Bitarães C, Cruz Milagres A, Diniz Callegari E, Campos Simplicio MI, Barra Ribeiro L, Oliveira R, Harari O, Wilson LA, Forrest JI, Ruton H, Sprague S, McKay P, Guo CM, Guyatt GH, Rayner CR, Boulware DR, Ezer N, Lee TC, McDonald EG, Bafadhel M, Butler C, Rodrigues Silva J, Dybul M, Mills EJ; TOGETHER Investigators. Reis G, et al. Ann Intern Med. 2023 May;176(5):667-675. doi: 10.7326/M22-3305. Epub 2023 Apr 18. Ann Intern Med. 2023. PMID: 37068273 Free PMC article. Clinical Trial.
BACKGROUND: Previous trials have demonstrated the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease progression among outpatients with COVID-19. OBJECTIVE: To determine whether the combination of fluvoxamine and inhaled budesonide w …
BACKGROUND: Previous trials have demonstrated the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease …
Budesonide for maintenance of remission in Crohn's disease.
Kuenzig ME, Rezaie A, Seow CH, Otley AR, Steinhart AH, Griffiths AM, Kaplan GG, Benchimol EI. Kuenzig ME, et al. Cochrane Database Syst Rev. 2014 Aug 21;2014(8):CD002913. doi: 10.1002/14651858.CD002913.pub3. Cochrane Database Syst Rev. 2014. PMID: 25141071 Free PMC article. Review.
SELECTION CRITERIA: Randomized controlled trials comparing budesonide to a control treatment, or comparing two doses of budesonide, were included. ...MAIN RESULTS: Twelve studies (n = 1273 patients) were included in the review: eight studies compared budesonide …
SELECTION CRITERIA: Randomized controlled trials comparing budesonide to a control treatment, or comparing two doses of budesonide …
1,755 results

Searches related to "budesonide"